Loading…
Relay Therapeutics, Inc. is projected to rise to $23.10 by 2027, a +19% move from its current price of $19.45. RLAY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $18.89 | $19.45 | $20.03 | +0.02% |
| Aug 2 | $18.66 | $19.46 | $20.28 | +0.04% |
| Aug 3 | $18.49 | $19.46 | $20.48 | +0.06% |
| Aug 4 | $18.35 | $19.47 | $20.65 | +0.08% |
| Aug 5 | $18.23 | $19.47 | $20.79 | +0.10% |
| Aug 6 | $18.12 | $19.47 | $20.93 | +0.12% |
| Aug 7 | $18.02 | $19.48 | $21.05 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.02 | $19.48 | $21.05 | +0.14% |
| Week 2 | $17.47 | $19.50 | $21.77 | +0.27% |
| Week 3 | $17.07 | $19.53 | $22.35 | +0.41% |
| Week 4 | $16.74 | $19.56 | $22.85 | +0.55% |
| Week 5 | $16.45 | $19.58 | $23.31 | +0.69% |
| Week 6 | $16.21 | $19.61 | $23.73 | +0.82% |
| Week 7 | $15.98 | $19.64 | $24.13 | +0.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer.
It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc.
for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc.
and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Relay Therapeutics, Inc. (RLAY) is a healthcare company focused on precision medicines in oncology and genetic disease indications. Its headquarters are in Cambridge, Massachusetts, and it was incorporated in 2015 after formerly being known as Allostery, Inc.
The company trades in the healthcare sector with a clinical-stage pipeline that includes RLY-2608, RLY-8161, and RLY-4008, among others, and engages in collaborations with notable research and industry partners.
A major floor 51.9% below — a decisive break under it would weaken the trend.
The nearest floor, 20.0% below — buyers have tended to step in here.
The nearest ceiling, 6.7% above — a clean break opens room to run.
A major ceiling 22.2% above — clearing it would confirm fresh momentum.
Key RLAY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RLAY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.64 | Buy | $18.87 | Buy |
| MA 10 | $18.99 | Buy | $18.91 | Buy |
| MA 20 | $19.22 | Buy | $18.72 | Buy |
| MA 50 | $16.87 | Buy | $17.23 | Buy |
| MA 100 | $14.73 | Buy | $15.09 | Buy |
| MA 200 | $11.29 | Buy | $12.26 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.06 | Neutral |
| Stoch RSI (14) | 64.87 | Neutral |
| CCI (20) | 32.72 | Neutral |
| Williams %R (14) | -28.40 | Info |
| MACD (12,26,9) | -0.24 | Sell |
| ROC (12) | 1.94 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 71.60 | Neutral |
| TRIX (15) | 0.61 | Buy |
| Awesome (5,34) | 0.40 | Buy |
| Ultimate (7,14,28) | 51.94 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 18.48 | Buy |
| ADX (14) | 18.22 | Neutral |
| ATR (14) | 0.50 | Info |
Current price is $19.18 with a market cap of $4.18B and a rank of 1426. The near-term technical picture is bullish with RSI(14) at 60 and SMA50 at $15.88 versus SMA200 at $10.77, suggesting an uptrend. Support sits at $13.49 and resistance at $20.75, while the thirty-day range runs from $15.41 to $23.87.
Annualized volatility sits at 60%, indicating notable price movements over the year.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.35 | $19.45 | $25.14 | 0% | Neutral | |
| $18.29 | $23.10 | $30.93 | +19% | Neutral | |
| $22.35 | $29.10 | $40.55 | +50% | Bullish | |
| $29.48 | $39.38 | $56.60 | +102% | Bullish | |
| $33.91 | $46.32 | $68.33 | +138% | Bullish | |
| $38.32 | $53.43 | $80.64 | +175% | Bullish | |
| $41.37 | $58.78 | $90.52 | +202% | Bullish | |
| $43.62 | $63.10 | $98.98 | +224% | Bullish | |
| $49.33 | $72.59 | $115.79 | +273% | Bullish | |
| $55.68 | $83.28 | $134.93 | +328% | Bullish | |
| $86.97 | $140.08 | $242.26 | +620% | Bullish | |
| $186.68 | $342.03 | $650.22 | +16.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.35 | $19.45 | $22.71 | +0.00% |
| August 2026 | $16.60 | $19.52 | $23.51 | +0.36% |
| September 2026 | $16.69 | $19.80 | $24.19 | +1.43% |
| October 2026 | $17.25 | $20.61 | $25.46 | +4.09% |
| November 2026 | $17.14 | $20.60 | $25.69 | -0.04% |
| December 2026 | $16.54 | $19.99 | $25.14 | -2.95% |
Click any year to see its month-by-month RLAY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RLAY could reach as high as $25.14, with a base case around $19.45 and support toward $7.35 — roughly 0% from $19.45. A consolidation phase looks the most probable path here.
Expect RLAY to range from $18.29 to $30.93 through 2027. The $23.10 average target implies a +19% move from current prices. That is up +19% on the projected 2026 average. Price action looks broadly range-bound.
The RLAY price prediction for 2028 points to an average of $29.10 (low $22.35, high $40.55) — a potential gain of +50% on today's $19.45. Buyers look set to stay in control over this stretch.
In 2029, RLAY is projected to trade between $29.48 and $56.60, averaging $39.38 — a potential gain of +102% from today's $19.45. That is up +35% on the projected 2028 average. Momentum favours further upside here.
Relay Therapeutics, Inc.'s 2030 outlook centres on $46.32, within a $33.91 to $68.33 range. That is up +18% on the projected 2029 average. That marks a +138% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, RLAY could reach as high as $80.64, with a base case around $53.43 and support toward $38.32 — roughly +175% from $19.45. Momentum favours further upside here.
Expect RLAY to range from $41.37 to $90.52 through 2032. The $58.78 average target implies a +202% move from current prices. That is up +10% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The RLAY price prediction for 2033 points to an average of $63.10 (low $43.62, high $98.98) — a potential gain of +224% on today's $19.45. Momentum favours further upside here.
In 2034, RLAY is projected to trade between $49.33 and $115.79, averaging $72.59 — a potential gain of +273% from today's $19.45. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Relay Therapeutics, Inc.'s 2035 outlook centres on $83.28, within a $55.68 to $134.93 range. That is up +15% on the projected 2034 average. That marks a +328% change versus current levels. Momentum favours further upside here.
By 2040, RLAY could reach as high as $242.26, with a base case around $140.08 and support toward $86.97 — roughly +620% from $19.45. Buyers look set to stay in control over this stretch.
Expect RLAY to range from $186.68 to $650.22 through 2050. The $342.03 average target implies a +16.6x move from current prices. That is up +144% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RLAY today (≈ 51.413882 RLAY) could be worth
$17,585.15
+$16,585.15 (+1659%) by 2050 · US Dollar
Based on the average projected RLAY price of $342.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RLAYwould be worth at today's price.
$1,000 invested in RLAY on Jul 30, 2025 (≈ 275.482085 RLAY) would be worth
$5,358.13
+$4,358.13 (+435.8%) today · 5.36× · US Dollar
Based on a RLAY entry price of $3.63 vs. today's $19.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.09 | $1,018.86 | +1.9% |
| 1 month ago | $18.71 | $1,039.55 | +4.0% |
| 3 months ago | $12.72 | $1,529.09 | +52.9% |
| 6 months ago | $7.66 | $2,539.16 | +153.9% |
| 1 year ago | $3.63 | $5,358.13 | +435.8% |
| All time (5.0y) ago | $33.02 | $589.04 | -41.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RLAY forecast.
Our base-case forecast reaches $39.00 around 2029.
Implied market cap at $39.00: $8.5B
The multi-year forecast shows a rising trajectory with several milestones. For 2026 the avg is $19.18, with a min of $7.35 and a max of $24.79; ROIPct is 0 and sentiment Neutral. In 2027, the avg rises to $22.76 (min $17.78, max $31.04; ROIPct 18.7; sentiment Neutral), and 2028 shows an avg of $27.85 (min $21.00, max $39.68; ROIPct 45.2; sentiment Bullish).
The forecast continues with 2029 avg $38.44 (min $28.16, max $56.67; ROIPct 100.4; sentiment Bullish) and 2030 avg $45.75 (min $32.66, max $69.39; ROIPct 138.5; sentiment Bullish).
Beyond 2030, the path remains bullish with 2031 avg $51.68, 2032 avg $57.34, and 2033 avg $61.03, all with positive ROI percentages and bullish sentiment. The uptrend extends to 2034 avg $68.21, 2035 avg $79.78, 2040 avg $132.67, and 2050 avg $327.81, with corresponding max values and increasingly strong bullish signals, culminating in a 2050 max of $654.47 and ROIPct 1609.1. These figures reflect higher, longer-term price expectations, balanced by typical market uncertainties and the inherent volatility of a clinical-stage healthcare stock.
Tap a question to reveal the answer.
2030 avg $45.75, min $32.66, max $69.39, ROI 138.5, sentiment Bullish.
Forecasts show bullish sentiment in several years with rising averages (e.g., 2027 avg $22.76, 2030 avg $45.75, 2040 avg $132.67, 2050 avg $327.81). However, these are estimates and not guarantees.
Yes. The forecast includes max values above $100 in multiple years, including 2034 max $112.66, 2040 max $239.22, and 2050 max $654.47.
Current price $19.18; market cap $4.18B.
Thirty-day range low $15.41 and high $23.87; annualized volatility 60%.
Relay Therapeutics, Inc. Community Discussion
0Share your Relay Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.